{
    "data": [
        {
            "id": "4565515",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-20T11:24:06-05:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1426691421/image_1426691421.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: Why The Company Is Still Undervalued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "426977",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4565515-merck-why-the-company-is-still-undervalued"
            }
        },
        {
            "id": "4564628",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-16T16:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 46,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387630788/image_1387630788.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna's Next $20B Franchise - Learning From Merck's Keytruda",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "425971",
                            "type": "sentiment"
                        },
                        {
                            "id": "425972",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4564628-moderna-next-20b-franchise-learning-from-merck-keytruda"
            }
        },
        {
            "id": "4563315",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-08T15:26:28-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/477645508/image_477645508.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Prometheus Biosciences A Buy On Positive Phase 2 Data",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "424838",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4563315-prometheus-biosciences-stock-buy-positive-phase-2-data"
            }
        },
        {
            "id": "4561440",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-30T13:13:32-05:00",
                "isLockedPro": false,
                "commentCount": 61,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/546430484/image_546430484.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: Hold For Quality, 11-Year Dividend Growth And 2.5% Yield",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "91485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "423155",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4561440-merck-hold-for-quality-11-year-dividend-growth-and-2-5-percent-yield"
            }
        },
        {
            "id": "4559710",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-22T11:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1370358685/image_1370358685.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck Vs. AbbVie: Which Is Better Buy As The Patent Cliffs Approach?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106588",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "416119",
                            "type": "sentiment"
                        },
                        {
                            "id": "416121",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4559710-merck-abbvie-stock-better-buy-patent-cliffs-approach"
            }
        },
        {
            "id": "4550976",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-30T16:42:48-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341267069/image_1341267069.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: Great Medicine For The Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "417443",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4550976-merck-great-medicine-for-the-portfolio"
            }
        },
        {
            "id": "4548954",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-25T14:34:32-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Prometheus Biosciences Best-Now Biotech Bet, Say Portfolio Wealth Builders",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23468",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "416284",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4548954-prometheus-biosciences-best-now-biotech-bet-say-portfolio-wealth-builders"
            }
        },
        {
            "id": "4548671",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-24T19:39:45-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/72561161/image_72561161.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: A Shield From Recession",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106231",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "416207",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4548671-merck-a-shield-from-recession"
            }
        },
        {
            "id": "4546462",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-13T16:37:34-04:00",
                "isLockedPro": false,
                "commentCount": 61,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387928661/image_1387928661.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck And Moderna Move Forward With Melanoma Vaccine - There's A Case For Backing Both",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "414306",
                            "type": "sentiment"
                        },
                        {
                            "id": "414307",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4546462-merck-and-moderna-move-forward-with-melanoma-vaccine-theres-a-case-for-backing-both"
            }
        },
        {
            "id": "4545810",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-11T08:05:41-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: Resilient To Macroeconomic Headwinds, Attractively Valued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "413730",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4545810-merck-resilient-to-macroeconomic-headwinds-stock-attractively-valued"
            }
        },
        {
            "id": "4542333",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-21T14:59:46-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1344413214/image_1344413214.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: A Gem In A Period Of Economic And Geopolitical Uncertainties",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "410344",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4542333-merck-a-gem-in-a-period-of-economic-and-geopolitical-uncertainties"
            }
        },
        {
            "id": "4538644",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-08T08:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/56293183/image_56293183.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck Benefits From Diagnosis Rate Pickup, Limited Risk To Medicare Bills",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105192",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "407243",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4538644-merck-benefits-from-diagnosis-rate-pickup-limited-risk-to-medicare-bills"
            }
        },
        {
            "id": "4539185",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-07T10:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1283195266/image_1283195266.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: 4 Reasons To Choose A Green Pill",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106588",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "407710",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4539185-merck-four-reasons-to-choose-a-green-pill"
            }
        },
        {
            "id": "4538536",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-01T17:25:19-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Outlook For Merck Continues To Be Favorable",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20102",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "407182",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4538536-outlook-for-merck-continues-to-be-favorable"
            }
        },
        {
            "id": "4528571",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-02T11:31:45-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341484868/image_1341484868.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: Strong Oncology Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106331",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "385449",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4528571-merck-strong-oncology-pipeline"
            }
        },
        {
            "id": "4528206",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-01T08:38:00-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1358625659/image_1358625659.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck And AbbVie Q2: Pipeline And Dividends In Focus",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "385430",
                            "type": "sentiment"
                        },
                        {
                            "id": "385431",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4528206-merck-abbvie-q2-pipeline-dividends-focus"
            }
        },
        {
            "id": "4526143",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-27T09:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184860418/image_184860418.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Merck Offers Plenty Of Value At Current Levels",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "384658",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4526143-merck-stock-offers-plenty-value-current-levels"
            }
        },
        {
            "id": "4525731",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-26T06:00:36-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1069877876/image_1069877876.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Top Defensive Stocks On The Eve Of The July Fed Meeting",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105600",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "384500",
                            "type": "sentiment"
                        },
                        {
                            "id": "384501",
                            "type": "sentiment"
                        },
                        {
                            "id": "384502",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4525731-3-top-defensive-stocks"
            }
        },
        {
            "id": "4524515",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-20T14:10:26-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1329399906/image_1329399906.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Long-Term Revenue Projections Suggest Merck Will Survive, Even Thrive, After Keytruda LOE",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "383630",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4524515-merck-will-thrive-after-keytruda-loe"
            }
        },
        {
            "id": "4521644",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-04T09:22:09-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1320732492/image_1320732492.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105063",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "381130",
                            "type": "sentiment"
                        },
                        {
                            "id": "381131",
                            "type": "sentiment"
                        },
                        {
                            "id": "381132",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4521644-buyout-pair-trade-buy-aurinia-sell-merck-seagen"
            }
        },
        {
            "id": "4520417",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-26T09:57:42-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/876353660/image_876353660.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Seagen Would Be A Great Fit For Merck",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40031",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "380016",
                            "type": "sentiment"
                        },
                        {
                            "id": "380017",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4520417-seagen-great-fit-for-merck"
            }
        },
        {
            "id": "4519705",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-22T11:15:22-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1324201139/image_1324201139.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck And Seagen: For And Against The Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104870",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "379450",
                            "type": "sentiment"
                        },
                        {
                            "id": "379451",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4519705-merck-and-seagen-for-and-against-the-deal"
            }
        },
        {
            "id": "4515572",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-31T17:30:51-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: Still Undervalued After 22% Return",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "376414",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4515572-merck-still-undervalued-after-22-percent-return"
            }
        },
        {
            "id": "4514379",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-25T12:00:47-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: Investment Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "375604",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4514379-merck-investment-opportunity"
            }
        },
        {
            "id": "4505631",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-01T05:56:49-04:00",
                "isLockedPro": false,
                "commentCount": 50,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1306383993/image_1306383993.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck Is A Rocket On The Launchpad",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "371898",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4505631-merck-is-rocket-on-launchpad"
            }
        },
        {
            "id": "4503174",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-24T02:12:38-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/520840309/image_520840309.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck Is Still A Strong Buy And Possibly Set To Fly To Record Highs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "370812",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4503174-merck-strong-buy-and-possibly-set-to-fly-to-record-highs"
            }
        },
        {
            "id": "4502753",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-21T15:25:41-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: Ties To D.C. Correlated With Revenue",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106575",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "369314",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4502753-merck-ties-to-dc-correlated-with-revenue"
            }
        },
        {
            "id": "4499010",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-31T13:00:39-04:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291181797/image_1291181797.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck Stock: Possibly The Best Big Pharma Buy Today",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "367890",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4499010-merck-best-big-pharma-buy"
            }
        },
        {
            "id": "4497417",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-23T17:44:04-04:00",
                "isLockedPro": false,
                "commentCount": 54,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1298030943/image_1298030943.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck And Altria: Opposites Providing Regular Growing Income",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106231",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "366818",
                            "type": "sentiment"
                        },
                        {
                            "id": "366819",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4497417-merck-and-altria-opposites-providing-regular-growing-income"
            }
        },
        {
            "id": "4496042",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-16T23:47:55-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1204124465/image_1204124465.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Positive Outlook For Merck",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20102",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "365866",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4496042-positive-outlook-for-merck"
            }
        },
        {
            "id": "4496024",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-16T21:50:42-04:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1307666883/image_1307666883.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why I Finally Got My Head Around Merck",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "365795",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4496024-merck-keytruda-underestimated-portfolio-diversified"
            }
        },
        {
            "id": "4486664",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-13T07:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 127,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/136360322/image_136360322.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Merck Today To Retire Rich Tomorrow",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24223",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "361286",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4486664-buy-merck-today-to-retire-rich-tomorrow"
            }
        },
        {
            "id": "4486646",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-13T02:19:56-05:00",
                "isLockedPro": false,
                "commentCount": 60,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/482987395/image_482987395.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck: Your Opportunity Is Knocking",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105703",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "361298",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4486646-merck-your-opportunity-is-knocking"
            }
        },
        {
            "id": "4485126",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-08T11:15:31-05:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289345741/image_1289345741.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pfizer Vs. Merck: Battle Between The Giants During Pandemic And Beyond",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "360471",
                            "type": "sentiment"
                        },
                        {
                            "id": "360472",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4485126-pfizer-vs-merck-battle-covid-19-pandemic-beyond"
            }
        },
        {
            "id": "4479531",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-13T12:32:39-05:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1259977836/image_1259977836.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Adding Merck To My High Quality Pharma Holdings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "356902",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4479531-adding-merck-to-my-pharma-holdings"
            }
        },
        {
            "id": "4478781",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-10T11:34:24-05:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1222001643/image_1222001643.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "356481",
                            "type": "sentiment"
                        },
                        {
                            "id": "356482",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4478781-merck-absci-ai-driven-drug-development-deal"
            }
        },
        {
            "id": "4477889",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-04T12:46:50-05:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/56293183/image_56293183.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merck & Co.: Attractive Valuation With Margin Stability In Focus",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "355382",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1422",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4477889-merck-and-co-attractive-valuation-margin-stability-in-focus"
            }
        }
    ]
}